Theophylline for Prevention of Contrast-Induced Nephropathy

Department of Critical Care Medicine, Calgary Health Region, and Departments of Internal Medicine, University of Calgary, Calgary, Alberta, Canada.
Archives of Internal Medicine (Impact Factor: 13.25). 06/2005; 165(10):1087-93. DOI: 10.1001/archinte.165.10.1087
Source: PubMed

ABSTRACT Contrast-induced nephropathy (CIN) is an important cause of declines in kidney function and is related to greater morbidity, health care costs, and mortality. Adenosine has been proposed to contribute to the pathophysiological process of CIN. We performed a systematic review and meta-analysis of theophylline, an adenosine antagonist, for the prevention of CIN.
Studies were identified in all languages by search of MEDLINE (1966 through November 2003), EMBASE (1980 through week 44 [November] of 2003), and the Cochrane Controlled Clinical Trials Register (1996 through November 2003) databases and selected conference proceedings.
We searched for randomized controlled trials comparing theophylline vs control in patients receiving radiocontrast media for angiography or computed tomography.
Our primary outcome measures were the risk of CIN, the difference in serum creatinine levels between theophylline and control groups at 48 hours and need for dialysis.
Nine randomized controlled trials involving 585 patients were identified and included for analysis. Theophylline protocols and definitions of CIN varied across studies. There was evidence of heterogeneity of results across trials (Q = 9.77; P = .08); therefore, pooled values require cautious interpretation. The overall pooled odds ratio (OR) using a conservative random-effects model was 0.40 (95% confidence interval [CI], 0.14 to 1.16; P = .09) indicating a trend toward reduction in the incidence of CIN with theophylline use. The pooled estimate for the difference in 48-hour serum creatinine levels between the theophylline and control groups was -0.17 mg/dL (95% CI, -0.28 to -0.06 mg/dL) (-15.2 micromol/L [95% CI, -24.6 to -5.7 micromol/L]) (P = .002), indicating that theophylline may be protective in CIN. The incidence of CIN requiring dialysis was uncommon and reported in only 1 case.
Theophylline may reduce the incidence of CIN with an efficacy that is perhaps comparable to that reported in studies of N-acetylcysteine. However, findings are inconsistent across studies. A large, well-designed trial that incorporates the evaluation of clinically relevant outcomes is required to more adequately assess the role for theophylline in CIN prevention.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This chapter describes the effects of the natural methylxanthines caffeine and theophylline on kidney function. Theophylline in particular was used traditionally to increase urine out put until more potent diuretics became available in the middle of the last century. The mildly diuretic actions of both methylxanthines are mainly the result of inhibition of tubular fluid reabsorption along the renal proximal tubule. Based upon the use of specific adenosine receptor antagonists and the observation of a complete loss of diuresis in mice with targeted deletion of the A1AR gene, transport inhibition by methylxanthines is mediated mainly by antagonism of adenosine A1 receptors (A1AR) in the proximal tubule. Methylxanthines are weak renal vasodilators, and they act as competitive antagonists against adenosine-induced preglomerular vasoconstriction. Caffeine and theophylline stimulate the secretion of renin by inhibition of adenosine receptors and removal of the general inhibitory brake function of endogenous adenosine. Since enhanced intrarenal adenosine levels lead to reduced glomerular filtration rate in several pathological conditions theophylline has been tested for its therapeutic potential in the renal impairment following administration of nephrotoxic substances such as radiocontrast media, cisplatin, calcineurin inhibitors or following ischemia-reperfusion injury. In experimental animals functional improvements have been observed in all of these conditions, but available clinical data in humans are insufficient to affirm a definite therapeutic efficacy of methylxanthines in the prevention of nephrotoxic or postischemic renal injury.
    Handbook of experimental pharmacology 01/2011; DOI:10.1007/978-3-642-13443-2_15
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Acute renal failure on the intensive care unit is associated with significant mortality and morbidity. To determine recommendations for the prevention of acute kidney injury (AKI), focusing on the role of potential preventative maneuvers including volume expansion, diuretics, use of inotropes, vasopressors/vasodilators, hormonal interventions, nutrition, and extracorporeal techniques. A systematic search of the literature was performed for studies using these potential protective agents in adult patients at risk for acute renal failure/kidney injury between 1966 and 2009. The following clinical conditions were considered: major surgery, critical illness, sepsis, shock, and use of potentially nephrotoxic drugs and radiocontrast media. Where possible the following endpoints were extracted: creatinine clearance, glomerular filtration rate, increase in serum creatinine, urine output, and markers of tubular injury. Clinical endpoints included the need for renal replacement therapy, length of stay, and mortality. Studies are graded according to the international Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) group system Several measures are recommended, though none carries grade 1A. We recommend prompt resuscitation of the circulation with special attention to providing adequate hydration whilst avoiding high-molecular-weight hydroxy-ethyl starch (HES) preparations, maintaining adequate blood pressure using vasopressors in vasodilatory shock. We suggest using vasopressors in vasodilatory hypotension, specific vasodilators under strict hemodynamic control, sodium bicarbonate for emergency procedures administering contrast media, and periprocedural hemofiltration in severe chronic renal insufficiency undergoing coronary intervention.
    Intensive Care Medicine 04/2010; 36(3):392-411. DOI:10.1007/s00134-009-1678-y · 5.54 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Die akute Pankreatitis ist potenziell lebensbedrohlich. Durch den z. T. fulminanten Verlauf ist das Zeitfenster für Diagnostik und Therapie kurz. Unter Berücksichtigung aktueller Leitlinien und mit Hilfe einer elektronischen Literatursuche wurden 12 Schlüsselfragen der Diagnostik und Therapie der akuten Pankreatitis zu beantworten versucht: Die Diagnose kann allein durch Anamnese, Klinik und Serumlipasebestimmung gestellt werden. Zum Nachweis einer biliären Genese sind Cholestaseparameter und Oberbauchsonographie ausreichend. Für die frühe Prognose eines schweren Verlaufs sind die Erhöhung von Blutzucker, Hämatokrit (Hkt) und Harnstoff (BUN, „blood urea nitrogen“) wegweisend. Die Bedeutung von erhöhtem Hkt und BUN legt eine frühe zielgerichtete Volumensubstitution nahe. Zur Schmerztherapie sind meist Opiate erforderlich. Metaanalysen belegen therapeutische Effekte der ERC (endoskopische retrograde Cholangiographie) bei biliärer Pankreatitis, der Antibiose bei nekrotisierender Pankreatitis und der frühzeitigen enteralen Ernährung. Auch beim Nachweis von Nekrosen ist ein konservatives Vorgehen gerechtfertigt. Bleibt dieses erfolglos, kann die chirurgische Therapie sinnvoll sein.
    Der Internist 07/2011; 52(7). DOI:10.1007/s00108-010-2796-x · 0.27 Impact Factor